Related Experiment Video
Updated: Sep 28, 2025
Immunomagnetic Separation of Fat Depot-specific Sca1high Adipose-derived Stem Cells ASCs
Published on: August 11, 2016
New insights on scleromyxedema
Laura Atzori1, Caterina Ferreli1, Franco Rongioletti1
1Dermatology Clinic, Department Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Abstract:
Scleromyxedema is a rare fibromucinous disorders, with several clinical and pathological overlaps with scleroderma and scleredema. Etiopathogenesis remains uncovered, and no explanation has been provided either for the origin of mucin deposition or for the paraprotein role. The disease does not show gender predilection and affects mainly middle-age adults. The course is unpredictable, and prognosis remains guarded for renal, cardiac, and neurologic complications, especially in the setting of dermato-neuro syndrome. A valuable recent progress is the consensus definition of diagnostic criteria and lines of treatment, which hold the promise to improve the early recognition and management of this rare condition worldwide. High-dose intravenous immunoglobulin has been suggested as the first-line treatment either alone or associated with systemic steroids and/or thalidomide. In very recalcitrant cases, adjunctive bortezomib and/or autologous stem cell transplant might be considered. Melphalan treatment was associated with very toxic side effects and actually is no longer recommended.
Insights
Scleromyxedema is a rare fibromucinous disorder. Current treatment guidelines suggest high-dose intravenous immunoglobulin as a first-line therapy, with other options for refractory cases.
Area of Science:
- Dermatology
- Rheumatology
- Internal Medicine
Background:
- Scleromyxedema is a rare fibromucinous disorder with overlapping features of scleroderma and scleredema.
- The underlying etiopathogenesis, including mucin deposition and paraprotein involvement, remains poorly understood.
- This condition affects middle-aged adults without gender predilection and has an unpredictable course.
Purpose of the Study:
- To summarize recent advancements in the consensus definition of diagnostic criteria for scleromyxedema.
- To outline current and emerging treatment strategies for this rare fibromucinous disorder.
- To highlight the importance of early recognition and management of scleromyxedema.
Main Methods:
- Review of recent literature on scleromyxedema diagnosis and treatment.
- Analysis of consensus guidelines for diagnostic criteria.
- Evaluation of treatment efficacy and safety profiles, including novel therapeutic approaches.
Main Results:
- Consensus diagnostic criteria have been established, aiding in earlier recognition.
- High-dose intravenous immunoglobulin is recommended as a first-line treatment, often combined with systemic steroids or thalidomide.
- Bortezomib and autologous stem cell transplant are options for refractory cases, while melphalan is no longer advised due to toxicity.
Conclusions:
- Standardized diagnostic criteria improve the identification of scleromyxedema.
- Intravenous immunoglobulin offers a promising first-line treatment approach.
- Careful consideration of treatment options is crucial for managing this complex fibromucinous disorder.
